Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemodynamic effects of RLX030 in acute heart failure (phase II, Germany)
2011-000833-35Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2011
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Acute Heart Failure (AHF) comparing RLX030 arm with Placebo arm (2 arms). Primary endpoint: Pulmonary capillary wedge pressure. Started Jun 2011; status: completed.
02
Drugs
serelaxin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2011-000833-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000833-35.